Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2689430 | 0.90 | SLC6A2 (0.48) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL2689802 | 0.89 | SLC6A2 (0.50) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL7332987 | 0.83 | ADRA1A (0.62) | ALDH1A1ADRA1ATAAR1 | |
| SCHEMBL14144590 | 0.83 | SLC13A5 (0.49) | ALDH1A1KDM4EADRA1ATAAR1 | |
| SCHEMBL30536248 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL2689127 | 0.82 | ALDH1A1 (0.52) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL31295055 | 0.81 | TAAR1 (0.44) | TAAR1 | |
| SCHEMBL910888 | 0.80 | CHRM2 (0.58) | ALDH1A1TAAR1 | |
| SCHEMBL18255318 | 0.79 | MEN1 (0.34) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL27828875 | 0.79 | CTSS (0.40) | ALDH1A1MEN1POLBHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2013-05-16 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168635-B2 | 2-(aminomethyl)-5-phenyltetrahydrofuran; 4-(3,4-Dimethoxyphenyl)-2-[5-(2-{5-[2-(5-fluoro-2-methoxyphenyl)-ethyl]-tetrahydrofuran-2-yl}-ethylamino)-pentyl]-4a,5,8,8a-tetrahydro-2H-phthalazin-1-one; dual inhibitor of serotonin reuptake and phosphodiesterase 4 (PDE4) enzyme activity | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-10-23 | — | — | US | disclosed |
| EP-1771435-A4 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RES INST (US) | 2008-02-13 | — | — | EP | disclosed |
| EP-1771435-A2 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | Human Biomolecular Research Institute (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006025920-A2 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | HUMAN BIOMOLECULAR RESEARCH INSTITUTE (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261967-A1 | Modulators of Central Nervous System Neurotransmitters | GAP43, SLC18A2, CHRNA6 | ALDH1A1 2537/4885MEN1 3652/4885POLB 4451/4885 |
| US-20130123253-A1 | MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS | GAP43, SLC18A2, CHRNA6 | ALDH1A1 2537/4885MEN1 3652/4885POLB 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.